View Exam | PowerPak

1. What is the minimum time until HIV protection is achieved in the rectal tissue with daily FTC/TDF PrEP use?

A. 3 days B. 7 days C. 10 days D. 20 days

2. How often must patients be screened for HIV while on PrEP?

A. Every month B. Every 3 months C. Every 6 months D. Annually

3. Which of the following is a side effect requiring monitoring while on PrEP?

A. Liver dysfunction B. Hyperglycemia C. Hyperlipidemia D. Renal dysfunction

4. When used appropriately, how effective is PrEP at reducing HIV acquisition?

A. > 90% B. 50-75% C. 25-50% D. < 25%

5. Please consider the following CASE:
Michael is a 19-year-old, African American gay male who presents to urgent care complaining of fever and malaise x 7 days. On physical exam, a nonspecific rash was noted on his trunk.

Past Medical History: n/a
Social History: He is sexually active however he is not in a monogamous relationship; last high risk sexual encounter was 3 weeks ago and reports 6 anonymous partners in the last 3 months with inconsistent condom use; smokes ½ pack per day x 1 year; binge drinks only on the weekends; denies illicit drug use; works as a waiter in New York City.
Medications: None
Allergies: No Known Drug Allergies
Vitals: Blood Pressure 106/72 Pulse 108 Temperature 101 F
Glomerular Filtration Rate > 60

Based on Michael's presentation, what is the preferred next step?

A. Start treatment for HIV now. Since he is symptomatic, you do not need an HIV test. B. Send Michael to the hospital. Based on his clinical presentation, he most likely has an opportunistic infection. C. Screen Michael for HIV using the fourth generation HIV antigen/antibody rapid test. D. Initiate Michael on post-exposure prophylaxis (PEP) with dolutegravir plus emtricitabine/tenofovir DF.

6. Which of the following is CORRECT regarding post-exposure prophylaxis for HIV?

A. Initiation of PEP should occur after HIV test results are available from the source patient. B. The preferred regimens include raltegravir OR dolutegravir + emtricitabine/tenofovir DF. C. The duration of PEP treatment is 7 days. D. Pharmacies in NYS are able to dispense a full treatment course of PEP utilizing a non-patient specific standing order.

7. When is HIV testing recommended for post-exposure prophylaxis?

A. Baseline only B. Four weeks after initiating antiretrovirals C. Twelve weeks after initiating antiretrovirals D. Baseline, 4 and 12 weeks after initiating antiretrovirals

8. In the case of nPEP, which of the following is the most accurate regarding the source patient?

A. Testing of the source patient is not recommended. B. If source patient reports being HIV-negative, nPEP is not indicated. C. If the source patient reports being HIV-positive, information on their antiretroviral regimens should be used to inform the regimen selected for nPEP. D. If the source patient reports being HIV-positive and undetectable, nPEP is not indicated.

9. Which of the following regimens is recommended for nPEP for a 23-year-old individual of child bearing potential?

A. Efavirenz/emtricitabine/tenofovor disoproxil fumarate B. Dolutegravir plus emtricitabine/tenofovir disoproxil fumarate C. Emtricitabine/tenofovir disoproxil fumarate D. Raltegravir plus emtricitabine/tenofovir disoproxil fumarate

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What is the minimum time until HIV protection is achieved in the rectal tissue with daily FTC/TDF PrEP use?

2. How often must patients be screened for HIV while on PrEP?

3. Which of the following is a side effect requiring monitoring while on PrEP?

4. When used appropriately, how effective is PrEP at reducing HIV acquisition?

6. Which of the following is CORRECT regarding post-exposure prophylaxis for HIV?

7. When is HIV testing recommended for post-exposure prophylaxis?

8. In the case of nPEP, which of the following is the most accurate regarding the source patient?

9. Which of the following regimens is recommended for nPEP for a 23-year-old individual of child bearing potential?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What is the minimum time until HIV protection is achieved in the rectal tissue with daily FTC/TDF PrEP use?

2. How often must patients be screened for HIV while on PrEP?

3. Which of the following is a side effect requiring monitoring while on PrEP?

4. When used appropriately, how effective is PrEP at reducing HIV acquisition?

6. Which of the following is CORRECT regarding post-exposure prophylaxis for HIV?

7. When is HIV testing recommended for post-exposure prophylaxis?

8. In the case of nPEP, which of the following is the most accurate regarding the source patient?

9. Which of the following regimens is recommended for nPEP for a 23-year-old individual of child bearing potential?

« Return to Activity

Customers who Purchased
this Activity also Purchased